Molecular Partners will present new data on its immuno-oncology pipeline at upcoming scientific conferences.
All posts by Thomas Schneckenburger
Molecular Partners published its Interim Management Statement for the period ending September 30, 2018, highlighting positive phase 3 efficacy data for abicipar, the ongoing clinical trials for MP0250 in oncology as well as further advancement of the immuno-oncology pipeline of the company.
Phase 3 safety and efficacy data of abicipar in patients with neovascular Age-related Macular Degeneration (nAMD) were presented at the American Academy of Ophthalmology (AAO) conference in Chicago. These data underline that abicipar has the potential to become the first fixed 12-week anti-VEGF therapeutic.
Molecular Partners announces its unaudited financial results for the first half-year 2018, including promising updated data on the phase 2 trial of its lead oncology asset MP0250 and the positive phase 3 topline data for abicipar, as announced on July 19, 2018 by the company’s strategic partner Allergan.
Allergan and Molecular Partners Announce Two Positive Phase 3 Clinical Trials for Abicipar pegol 8 and 12-week Regimens for the Treatment in Patients with Neovascular Age-Related Macular Degeneration
Molecular Partners announces the appointment of PamelaTrail as Chief Scientific Officer and Michael Stumpp as Chief Operating Officer of the company.
Molecular Partners presents updated preliminary results from its ongoing Phase 2 study of MP0250 at the European Hematology Association (EHA) in Stockholm.
Molecular Partners presents the complete safety and efficacy results of the Phase 1 study of its lead proprietary oncology drug MP0250 at the Annual Meeting 2018 of the American Society of Clinical Oncology (ASCO) in Chicago.
Molecular Partners announces its Interim Management Statement for the period ending March 31, 2018.
Molecular Partners presented preliminary results from the ongoing Phase 2 study of MP0250 with bortezomib and dexamethasone in patients with relapsed refractory multiple myeloma (RRMM) at the 1st European Myeloma Network Meeting in Turin.